Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy

Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3289-3294. doi: 10.1007/s00259-022-05756-2. Epub 2022 Mar 17.

Abstract

Purpose: The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy.

Methods: We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and 68 Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan-Meier analysis.

Results: After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters.

Conclusion: These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS.

Keywords: Biochemical failure; Gleason score; PET/CT; PSMA; Prostate-specific membrane antigen; Radical prostatectomy.

MeSH terms

  • Gallium Radioisotopes
  • Humans
  • Male
  • Positron Emission Tomography Computed Tomography / methods
  • Prognosis
  • Prostate* / pathology
  • Prostate-Specific Antigen / analysis
  • Prostatectomy
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / surgery
  • Retrospective Studies

Substances

  • Gallium Radioisotopes
  • Prostate-Specific Antigen